Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2017 09:00 ET | Source: Novelion Therapeutics, Inc.

Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology

VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new...
January 07, 2016 09:24 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer

CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
November 20, 2015 08:30 ET | Source: Aegerion Pharmaceuticals, Inc.

JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
June 16, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety

CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
May 04, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces First Quarter 2015 Financial Results

- Company records $59.4 million in total net product sales - - JUXTAPID® net product sales of $57.3 million in the first quarter of 2015 represents 112% growth over the first quarter of 2014...
February 28, 2015 07:15 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Observes Rare Disease Day

CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
February 26, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results

- Company records $158.4 million in net product sales of JUXTAPID® in 2014, representing 226% growth over 2013 - - Company generates $17.9 million in positive cash flow from operations in the...
February 25, 2015 16:10 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference

CAMBRIDGE, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
February 10, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
January 20, 2014 08:00 ET | Source: Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals' JUXTAPID(R) (lomitapide) Capsules Approved in Mexico for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

CAMBRIDGE, Mass., Jan. 20, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...

Next Page keyboard_arrow_right